secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-105904
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20
-------------------------------------------------------------------

- Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).
- Net loss ($54.3M) or ($0.82)/share vs ($45.0M) or ($0.73)/share a year ago.
- Cash and investments $416.1M at Sep 30, 2025, up from $320.6M at Dec 31, 2024.
- Updated FY2025 non-GAAP operating expense guidance $295M-$315M excluding stock-based compensation.
- PDUFA date Dec 20, 2025 for setmelanotide sNDA in acquired hypothalamic obesity; Phase 2 PWS data Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/0001104659-25-105904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer